FibroBiologics Files IND Application with the U.S. FDA to Advance Clinical Development of CYPS317 in Patients with Psoriasis

Stock Information for FibroBiologics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FibroBiologics Inc.

FibroBiologics to Present at the DealFlow Discovery Conference
FibroBiologics CEO Issues Letter to Shareholders
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
FibroBiologics Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FibroBiologics Announces $1.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
FibroBiologics Files Patent Application Covering Novel Fibroblast-Based Chondrocyte Spheroid Platform for Orthopedic and Musculoskeletal Conditions
FibroBiologics Announces Payoff of Outstanding Debt

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.